Calcium kinetics in heart failure progression;Cinética do cálcio na progressão da insuficiência cardíaca

Revista Portuguesa de Cardiologia

Volumn 23, Issue SUPPL. 2, 2004, Pages

  Roncon Albuquerque Jr , Roberto ^a   Leite Moreira, Adelino F ^a,b  

^a University of Porto   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Calcium kinetics; Gene therapy; Heart failure; Myocardium

Indexed keywords

CALCIUM; GENE PRODUCT; PROTEIN SERCA2; UNCLASSIFIED DRUG;

ACTION POTENTIAL; CALCIUM HOMEOSTASIS; CALCIUM SIGNALING; CALCIUM TRANSPORT; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; EXCITATION CONTRACTION COUPLING; EXTRACELLULAR SPACE; GENE EXPRESSION; GENE TRANSFER; GENETIC CODE; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR MECHANICS; MYOFILAMENT; REGULATORY MECHANISM; REVIEW; SARCOPLASMIC RETICULUM; SYSTOLIC BLOOD PRESSURE;

CALCIUM; CALCIUM CHANNELS; DISEASE PROGRESSION; GENE THERAPY; HEART FAILURE, CONGESTIVE; HOMEOSTASIS; HUMANS; MYOCYTES, CARDIAC;

EID: 3142668361     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Bers DM. Cardiac excitation-contraction coupling. Nature 2002;415:198-205.
2. Pieske B. Alterations in excitation-contraction coupling and potential gene therapy targets in failing human hearts. In: Hasenfuss G, Marban E, editors. Molecular approaches to heart failure therapy. Steinkopff Verlag, Darmstadt. 2000:5-25.
3. Houser SR, Piacentino V 3rd, Weisser J. Abnormalities of calcium cycling in the hypertrophied and failing heart. J Mol Cell Cardiol 2000;32:1595-607.
4. 2+ content in isolated failing and nonfailing human myocardium. Circ Res 1999;85:38-46.
5. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part 1: diagnosis, prognosis, and measurements of diastolic function. Circulation 2002; 105:1387-93.
6. Yla-Herttuala S, Martin JF. Cardiovascular gene therapy. Lancet 2000;355:213-22.
7. Isner JM. Myocardial gene therapy. Nature 2002;415:234-9.
8. Hoshijima M, Ikeda Y, Iwanaga Y, Minamisawa S, Date MO, Gu Y, Iwatate M, Li M, Wang L, Wilson JM, Wang Y, Ross J Jr, Chien KR. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 2002;8:864-71.
9. 2+ buffering in rabbit ventricular myocytes. Am J Physiol 1996;270:C192-9.
10. Bers DM. Calcium fluxes involved in control of cardiac myocyte contraction. Circ Res 2000;87:275-81.
11. Leblanc N, Hume JR. Sodium current-induced release of calcium from cardiac sarcoplasmic reticulum. Science 1990; 248:372-6.
12. Trafford AW, Diaz ME, O'Neill SC, Eisner DA. Comparison of subsarcolemmal and bulk calcium concentration during spontaneous calcium release in rat ventricular myocytes. J Physiol 1995;488:577-86.
13. 2+ transient of failing human ventricular myocytes. Circ Res 1999;84:435-44.
14. Marban E. Cardiac channelopathies. Nature 2002;415: 213-8.
15. Pogwizd SM, Schlotthauer K, Li L, Yuan W, Bers DM. Arrhythmogenesis and contractile dysfunction in heart failure: Roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness. Circ Res 2001;88:1159-67.
16. Sipido KR, Volders PG, Vos MA, Verdonck F. Altered Na/Ca exchange activity in cardiac hypertrophy and heart failure: a new target for therapy? Cardiovasc Res 2002;53: 782-805.
17. Agganval R, Shorofsky SR, Goldman L, Balke CW. Tetrodotoxin-blockable calcium currents in rat ventricular myocytes; a third type of cardiac cell sodium current. J Physiol 1997;505:353-69.
18. + channels: slip-mode conductance. Science 1998;279:1027-33.
19. 2+ flux through promiscuous cardiac Na+ channels: slip-mode conductance. Science 1998;279:1027-33.
20. Nuss HB, Marban E. Whether "slip-mode conductance" occurs. Science 1999;284;711a.
21. Cruz JDS, et al. Whether "slip-mode conductance" occurs. Science 1999;284;711a.
22. Zuhlke RD, Pitt GS, Deisseroth K, Tsien RW, Reuter H. Calmodulin supports both inactivation and facilitation of L-type calcium channels. Nature 1999;399:159-62.
23. 2+ release by a local inactivation of ryanodine receptors in cardiac myocytes. Proc Natl Acad Sci USA 1998;95:15096-101.
24. Prestle J, Janssen PML, Hasenfuss G. Overexpression of FKBP12.6 to influence SR function. In: Hasenfuss G, Marban E, editors. Molecular approaches to heart failure therapy. Steinkopff Verlag, Darmstadt. 2000:89-99.
25. 2+ sensitivity of skeletal and cardiac muscle ryanodine receptors in the presence of calmodulin. Am J Physiol Cell Physiol 2000;279:C724-33.
26. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N, Marks AR. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 2000;101:365-76.
27. Marx SO, Reiken S, Hisamatsu Y, Gaburjakova M, Gaburjakova J, Yang YM, Rosemblit N, Marks AR. Phosphorylation-dependent regulation of ryanodine receptors: a novel role for leucine/isoleucine zippers. J Cell Biol 2001;153:699-708.
28. Meyers MB, Puri TS, Chien AJ, Gao T, Hsu PH, Hosey MM, Fishman GI. Sorcin associates with the pore-forming subunit of voltage-dependent L-type Ca2+ channels. J Biol Chem 1998;273:18930-5.
29. Zhang L, Kelley J, Schmeisser G, Kobayashi YM, Jones LR. Complex formation between junctin, triadin, calsequestrin, and the ryanodine receptor. Proteins of the cardiac junctional sarcoplasmic reticulum membrane. J Biol Chem 1997;272:23389-97.
30. 2+ release units and couplons in skeletal and cardiac muscles. Biophys J 1999;77:1528-39.
31. Cheng H, Lederer WJ, Cannell MB. Calcium sparks: elementary events underlying excitation-contraction coupling in heart muscle. Science 1993;262:740-4.
32. 2+ sparks, and local control of excitation-contraction coupling in normal heart muscle. Circ Res 1999;85:770-6.
33. Bassani JW, Bassani RA, Bers DM. Relaxation in rabbit and rat cardiac cells: species-dependent differences in cellular mechanisms. J Physiol 1994;476:279-93.
34. Bers DM. Cardiac Na/Ca Exchange Function in Rabbit, Mouse and Man: What's the Difference? J Mol Cell Cardiol 2002;34:369-73.
35. 2+-ATPase isoform transcripts. Am J Physiol 1995;269:C775-84.
36. Chami M, Gozuacik D, Lagorce D, Brini M, Falson P, Peaucellier G, Pinton P, Lecoeur H, Gougeon ML, le Maire M, Rizzuto R, Brechot C, Paterlini-Brechot P. SERCA1 truncated proteins unable to pump calcium reduce the endoplasmic reticulum calcium concentration and induce apoptosis. J Cell Biol 2001;153:1301-14.
37. 2+ pumps and their modulation by phospholamban. Biochem J 1992;286:591-5.
38. 2+ ATPases: a plural, species-specific, and multiple hypertension-regulated expression system. Hypertension 2000;35:91-102.
39. 2+-ATPase of human fast-twitch skeletal muscle sarcoplasmic reticulum, and its elimination as a candidate gene for Brody disease. Genomics 1995;30:415-24.
40. Sande JB, Sjaastad I, Hoen IB, Bokenes J, Tonnessen T, Holt E, Lunde PK, Christensen G. Reduced level of serine(16) phosphorylated phospholamban in the failing rat myocardium: a major contributor to reduced SERCA2 activity. Cardiovasc Res 2002;53:382-91.
41. Schmidt AG, Kranias EG. Genetic approaches to elucidate the regulatory role of phospholamban in the heart. In: Hasenfuss G, Marban E, editors. Molecular approaches to heart failure therapy. Steinkopff Verlag, Darmstadt. 2000:39-52.
42. Kranias EG, Solaro RJ. Phosphorylation of troponin I and phospholamban during catecholamine stimulation of rabbit heart. Nature 1982;298:182-4.
43. Li L, Chu G, Kranias EG, Bers DM. Cardiac myocyte calcium transport in phospholamban knockout mouse: relaxation and endogenous CaMKII effects. Am J Physiol 1998; 274:H1335-47.
44. Bassani RA, Bassani JW, Bers DM. Relaxation in ferret ventricular myocytes: unusual interplay among calcium transport systems. J Physiol 1994;476:295-308.
45. Bassani RA, Bassani JW, Bers DM. Relaxation in ferret ventricular myocytes: role of the sarcolemmal Ca ATPase. Pflugers Arch 1995;430:573-8.
46. 2+ transients during rapid cooling contractures in guinea-pig ventricular myocytes. J Physiol 1989;417:537-53.
47. 2+ handling and sarcoplasmic reticulum Ca2+ content in isolated failing and nonfailing human myocardium. Circ Res 1999; 85:38-46.
48. 2+ uptake and thapsigargin sensitivity in permeabilized rabbit and rat ventricular myocytes. Circ Res 1993;73:820-8.
49. Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 1999;51:651-90.
50. Li L, Desantiago J, Chu G, Kranias EG, Bers DM. Phosphorylation of phospholamban and troponin I in beta-adrenergic-induced acceleration of cardiac relaxation. Am J Physiol Heart Circ Physiol 2000;278:H769-79.
51. Kentish JC, McCloskey DT, Layland J, Palmer S, Leiden JM, Martin AF, Solaro RJ. Phosphorylation of troponin I by protein kinase A accelerates relaxation and crossbridge cycle kinetics in mouse ventricular muscle. Circ Res 2001; 88:1059-65.
52. 2+ release cascade by beta-adrenergic stimulation in rat ventricular myocytes. J Physiol 2001;533: 837-48.
53. 2+ release during excitation-contraction coupling in cardiac myocytes. Circ Res 2001;88:794-801.
54. 2+ channel Cav1.2. Science 2001;293:98-101.
55. Rybin VO, Xu X, Steinberg SF. Activated protein kinase C isoforms target to cardiomyocyte caveolae: stimulation of local protein phosphorylation. Circ Res 1999;84:980-8.
56. Vila Petroff MG, Egan JM, Wang X, Sollot SJ. Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocites. Circ Res 2001;84:445-52.
57. Milano CA, Allen LF, Rockman HA, Dolber PC, McMinn TR, Chien KR, Johnson TD, Bond RA, Lefkowitz RJ. Enhanced myocardial function in transgenic mice overexpressing the b2-adrenergic receptor. Science 1994;264: 582-6.
58. Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in bl-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 1999;96:7059-64.
59. Lohse MJ, Benovic JL, Codina J, Caron MG, Lefkowitz RJ. Beta-arrestin: a protein that regulates beta-adrenergic receptor function. Science 1990;248:1547-50.
60. Lohse MJ, Andexinger S, Pitcher J, Trukawinski S, Codina J, Faure JP, Caron MG, Lefkowitz RJ. Receptor-specific desensitization with purified proteins. Kinase dependence and receptor specificity of beta-arrestin and arrestin in the beta 2-adrenergic receptor and rhodopsin systems. J Biol Chem 1992;267:8558-64.
61. Nantel F, Bonin H, Emorine LJ, Zilberfarb V, Strosberg AD, Bouvier M, Marullo S. The human beta 3-adrenergic receptor is resistant to short term agonist-promoted desensitization. Mol Pharmacol 1993;43:548-55.
62. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 1982;307:205-11.
63. Brodde OE. Beta-adrenoceptors in cardiac disease. Pharmacol Ther 1993;60:405-30.
64. Bristow MR, Minobe WA, Raynolds MV, Port JD, Rasmussen R, Ray PE, Feldman AM. Reduced beta 1 receptor messenger RNA abundance in the failing human heart. J Clin Invest 1993;92:2737-45.
65. Ungerer M, Bohm M, Elce JS, Erdmann E, Lohse MJ. Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation 1993;87:454-63.
66. Gauthier C, Tavernier G, Charpentier F, Langin D, Le Marec H. Functional beta3-adrenoceptor in the human heart. J Clin Invest 1996;98:556-62.
67. Cheng HJ, Zhang ZS, Onishi K, Ukai T, Sane DC, Cheng CP. Upregulation of functional beta 3-adrenergic receptor in the failing canine myocardium. Circ Res 2001;89:599-606.
68. Moniotte S, Balligand JL. Potential use of beta 3-adrenoceptor antagonists in heart failure therapy. Cardiovasc Drug Rev 2002;20:19-26.
69. Kaufmann AJ, Molenaar P. Modulation of human cardiac function through 4 b-adrenoceptor populations. Naunyn-Schmiedeberg's Arch Pharmacol 1997;355:667-81.
70. Hoshijima M, Chien KR. Mixed signals in heart failure: cancer rules. J Clin Invest 2002;109:849-55.
71. del Monte F, Harding SE, Schmidt U, Matsui T, Kang ZB, Dec GW, Gwathmey JK, Rosenzweig A, Hajjar RJ. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation 1999;100:2308-11.
72. Kaab S, Nuss HB, Chiamvimonvat N, O'Rourke B, Pak PH, Kass DA, Marban E, Tomaselli GF. Ionic mechanism of action potential prolongation in ventricular myocytes from dogs with pacing-induced heart failure. Circ Res 1996;78: 262-73.
73. Nuss HB, Houser SR. Effect of duration of depolarisation on contraction of normal and hypertrophied feline ventricular myocytes. Cardiovasc Res 1994;28:1482-9.
74. 2+ handling in isolated rat myocardium. Am J Physiol 1998;274:H1361-70.
75. 2+ homeostasis in monocrotaline-induced right ventricular hypertrophy of the rat. European Heart Journal 2002;23(Abstr. Suppl.):329.
76. Roncon-Albuquerque R Jr, Correia-Pinto J, Koegler H, Hartmann O, Nguyen Van P, Henriques-Coelho T, Brodde OE, Hasenfuss G, Leite-Moreira AF. 'Afterload-induced diastolic dysfunction, SERCA2a and PLB gene expression in the development of heart failure'. Abstract Book of the "Annual winter meeting of the Working Group on Myocardial Function of the European Society of Cardiology: From Hypertrophy to Failure". January 25-26, 2002; Isola2000, France.
77. Gwathmey JK, Copelas L, MacKinnon R, Schoen FJ, Feldman MD, Grossman W, Morgan JP. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res 1987;61:70-6.
78. Morgan JP. Abnormal intracellular modulation of calcium as a major cause of cardiac contractile dysfunction. N Engl J Med 1991;325:625-32.
79. Perez NG, Hashimoto K, McCune S, Altschuld RA, Marban E. Origin of contractile dysfunction in heart failure: calcium cycling versus myofilaments. Circulation 1999;99: 1077-83.
80. 2+-handling and sarcoplasmic reticulum Ca2+-content in isolated rat and rabbit myocardium. J Mol Cell Cardiol 2000;32:2249-58.
81. Bassani RA, Bers DM. Na-Ca exchange is required for rest-decay but not for rest-potentiation of twitches in rabbit and rat ventricular myocytes. J Mol Cell Cardiol 1994;26: 1335-47.
82. Arai M, Alpert NR, MacLennan DH, Barton P, Periasamy M. Alterations in sarcoplasmic reticulum gene expression in human heart failure. A possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. Circ Res 1993;72:463-9.
83. 2+-ATPase gene expression in the human ventricle during end-stage heart failure. J Clin Invest 1990;85:305-9.
84. 2+-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation 1995;92: 3220-8.
85. Feldman AM, Weinberg EO, Ray PE, Lorell BH. Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. Circ Res 1993;73:184-92.
86. Linck B, Boknik P, Eschenhagen T, Muller FU, Neumann J, Nose M, Jones LR, Schmitz W, Scholz H. Messenger RNA expression and immunological quantification of phospholamban and SR-Ca2+-ATPase in failing and nonfailing human hearts. Cardiovasc Res 1996;31:625-32.
87. 2+ channel) and calsequestrin genes in the myocardium of patients with end-stage heart failure. J Clin Invest 1992;90:927-35.
88. Meyer M, Schillinger W, Pieske B, Holubarsch C, Heilmann C, Posival H, Kuwajima G, Mikoshiba K, Just H, Hasenfuss G, et al. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 1995;92:778-84.
89. 2+ exchanger in end-stage human heart failure. Circ Res 1994;75:443-53.
90. 2+-ATPase in failing and nonfailing human myocardium. Circ Res 1994;75:434-42.
91. 2+ uptake by cardiac sarcoplasmic reticulum from patients with idiopathic dilated cardiomyopathy. Circ Res 1989;65:1141-4.
92. Schmidt U, Hajjar RJ, Helm PA, Kim CS, Doye AA, Gwathmey JK. Contribution of abnormal sarcoplasmic reticulum ATPase activity to systolic and diastolic dysfunction in human heart failure. J Mol Cell Cardiol 1998;30:1929-37.
93. 2+ exchanger cDNA. Proc Natl Acad Sci USA 1992;89:4769-73.
94. 2+ exchanger in failing human myocardium. Circulation 1996; 94:992-1002.
95. 2+ exchanger protein levels in human heart failure. Circulation 1999;99: 2105-12.
96. 2+ exchange activity in patients with end-stage heart failure. Cardiovasc Res 1996;31:48-54.
97. Brillantes AM, Allen P, Takahashi T, Izumo S, Marks AR. Differences in cardiac calcium release channel (ryanodine receptor) expression in myocardium from patients with end-stage heart failure caused by ischemic versus dilated cardiomyopathy. Circ Res 1992;71:18-26.
98. Go LO, Moschella MC, Watras J, Handa KK, Fyfe BS, Marks AR. Differential regulation of two types of intracellular calcium release channels during end-stage heart failure. J Clin Invest 1995;95:888-94.
99. Schillinger W, Meyer M, Kuwajima G, Mikoshiba K, Just H, Hasenfuss G. Unaltered ryanodine receptor protein levels in ischemic cardiomyopathy. Mol Cell Biochem 1996;160-161:297-302.
100. Mattiello JA, Margulies KB, Jeevanandam V, Houser SR. Contribution of reverse-mode sodium-calcium exchange to contractions in failing human left ventricular myocytes. Cardiovasc Res 1998;37:424-31.
101. Bassani RA, Bassani JW, Bers DM. Relaxation in ferret ventricular myocytes: unusual interplay among calcium transport systems. J Physiol 1994;476:295-308.
102. Beuckelmann DJ, Nabauer M, Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 1992;85: 1046-55.
103. Gaughan JP, Furukawa S, Jeevanandam V, Hefner CA, Kubo H, Margulies KB, McGowan BS, Mattiello JA, Dipla K, Piacentino V 3rd, Li S, Houser SR. Sodium/calcium exchange contributes to contraction and relaxation in failed human ventricular myocytes. Am J Physiol 1999;277:H714-24.
104. 2+ release from the sarcoplasmic reticulum in human ventricular myocytes from end-stage heart failure. Cardiovasc Res. 1998;37:478-88.
105. 2+-ATPase in a rat model of heart failure. Circulation 2001;104:1424-9.
106. Miyamoto MI, del Monte F, Schmidt U, DiSalvo TS, Kang ZB, Matsui T, Guerrero JL, Gwathmey JK, Rosenzweig A, Hajjar RJ. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci USA 2000; 97:793-8.
107. 2+-ATPase in failing and nonfailing human hearts. Cardiovasc Res 1996;31:625-32.
108. Meyer M, Bluhm WF, He H, Post SR, Giordano FJ, Lew WY, Dillmann WH. Phospholamban-to-SERCA2 ratio controls the force-frequency relationship. Am J Physiol 1999;276:H779-85.
109. 2+-ATPase activity and phosphorylation level of phospholamban. Am J Physiol 1999;277:H474-80.
110. del Monte F, Harding SE, Dec GW, Gwathmey JK, Hajjar RJ. Targeting phospholamban by gene transfer in human heart failure. Circulation 2002;105:904-7.
111. Sipido KR, Volders PG, Vos MA, Verdonck F. Altered Na/Ca exchange activity in cardiac hypertrophy and heart failure: a new target for therapy? Cardiovasc Res 2002; 53:782-805.
112. 2+ homeostasis in rabbits with pacing-induced heart failure. Am J Physiol 1998;275:H1441-8.
113. Pogwizd SM, Qi M, Yuan W, Samarel AM, Bers DM. Upregulation of Na(+)/Ca(2+) exchanger expression and function in an arrhythmogenic rabbit model of heart failure. Circ Res 1999;85:1009-19.
114. Brooks WW, Bing OH, Boluyt MO, Malhotra A, Morgan JP, Satoh N, Colucci WS, Conrad CH. Altered inotropic responsiveness and gene expression of hypertrophied myocardium with captopril. Hypertension 2000;35:1203-9.
115. 2+-exchanger protein levels and diastolic function of failing human myocardium. Circulation 1999;99: 641-8.
116. Ceia F, Fonseca C, Mota T, Morais H, Matias F, de Sousa A, Oliveira A, EPICA Investigators o O. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur J Heart Fail. 2002;4:531-9.
117. Leiden JM. Human gene therapy: the good, the bad, and the ugly. Circ Res 2000;86:923-5.
118. 2+ exchanger. Circ Res 2000;87:581-7.
119. Hashimoto K, Perez NG, Kusuoka H, Baker DL, Periasamy M, Marban E. Frequency-dependent changes in calcium cycling and contractile activation in SERCA2a transgenic mice. Basic Res Cardiol 2000;95:144-51.
120. Minamisawa S, Hoshijima M, Chu G, Ward CA, Frank K, Gu Y, Martone ME, Wang Y, Ross J Jr, Kranias EG, Giles WR, Chien KR. Chronic phospholamban- sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 1999; 99:313-22.